разбирал фундаментальные показатели по NFX, входит в S&P, грубая ошибка, шортать сильную акцию из индекса

BUD неликвид и FDR. Я только что был подвергнут критике за то, что торговал его вчера.

в моменте бумага слабее рынка, ниже вивап, через 20 ц. сопротивления, ну сдался тот лонг? По шортам, хорошо.

BABA , так если рынок не с ней, то какой разворот?

(US) Select Premarket Movers
Fri, 06 Mar 2015 9:21 AM EST

Upside:
-AVEO +17% (earnings & announcement of Phase 2 results Tivozanib)
-LTM +14% (premarket strength attributed to LBO speculation)
-YY +9% (earnings)
-MSO +8% (earnings)
-SKUL +7% (earnings)
-FNSR +6% (earnings)
-FL +5.2% (earnings)
-TFM +4.7% (earnings)
-THO +3.5% (earnings)
-BAC +2.5% (stress test results; C also up marginally)
-AA +2% (announced strategic review of smelting & refining capacity)
-BIG +2% (earnings)
-AAPL +1.5% (joining the DJIA 3/18, replacing T)
-MRVL +1.3% (positive broker commentary)

Downside:
-SSH -30% (update on US study of C-Pulse Heart Assist System)
-OREX -16% (top FDA official says Contrave data showing heart benefit are unreliable)
-CKP -15% (earnings)
-GENE -14.5% (announced A$18.6M capital raise)
-LULU -3.5% (negative broker commentary)
-SPLS -2.2% (earnings)
-GPS -1.5% (Fed SSS)
-ZION -1.5% (stress test results)
-GS -1.4% (stress test results)
-T -1% (being replaced on the DJIA by AAPL)
-ITCI -1% (priced 4.75M shares at $24/shr)

(US) Select Premarket Movers
Thu, 05 Mar 2015 9:19 AM EST

Upside:
-KYTH +25% (FDA staff notes show ATX-101 presents a consistent & favorable safety profile)
-BIOL +22% (earnings)
-EYES +20% (first successful implantation of the Argus II retinal prosthesis system)
-MVIS +14% (licensed PicoP display tech to Fortune Global 100 partner)
-CLDN +14% (initiated with Buy at Roth; expected to announce pivotal trial results from CUPID-2 trial in April '15)
-ARWR +11% (acquired NVS's RNAi R&D portfolio)
-TEAR +11% (announced $35M term loan agreement with CRG)
-PCYC +10% (being acquired by ABBV)
-VSLR +8.5% (earnings)
-MAC +7.3% (SPG said to have made takeover approach)
-MLR +7% (earnings)
-GDOT +6.3% (raised to Outperform from Neutral by Credit Suisse)
-KR +5.3% (earnings)
-RNDY +5.7% (earnings)
- CSIQ +5% (earnings, to form YieldCo)
-MBLY +4.4% (hearing strength attributed to introduction of the 4th generation system-on-chip the Eye4 engineering samples of EyeQ4 expected by Q4 FY15)
-MNK +2.4% (expands hospitals growth platform with Ikaria)
-COST +2.3% (earnings)
-HRTG +2% (earnings)
-SPG +0.8% (said to have made takeover offer for MAC)

Downside:
-ERJ -14% (earnings and FCF may be negative in FY15 due to heavy investment spending)
-VNDA -7% (announced Tradipitant Phase 2 proof of concept study results)
-JOY -6.7% (earnings)
-ABBV -6% (acquiring PCYC)
-HRB -4.3% (earnings)
-ACHN -4% (earnings)
-ARI -3.8% (offering 10M shares of common stock)
-DRII -3.2% (upsized offering to 6.7M share priced at $33.75/shr)
-HTLD -1% (priced 3.25M shares at $23.75/shr)
-GD -0.3% (increased dividend 11%)

Расскажите поподробнее, насколько большой был имбэланс.
А так стак red to green, консолидация на уровне клоуза с ретестом ... Просто идеально, чтобы добавиться. Зафиксили бы 40%-60% и сидеть дальше.